# Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation

> **NCT00402363** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 663 (actual)

## Conditions studied

- Fibrillation, Atrial

## Interventions

- **DRUG:** omega-3-acid ethyl esters
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00402363
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 663 (ACTUAL)
- **Last updated:** 2017-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00402363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00402363, "Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00402363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*